Inecalcitol.
Research-backed compound with potential health benefits.
Reviewed March 2026
- Category
- Compound
What Inecalcitol is, and what it does.
- Does it work
- Not available as supplement. Pharmaceutical in development.
- How much to take
- 1mg to 4mg a day is the band on record. The 8mg figure comes from studies, which is a research condition, and amounts for an investigational compound belong with a clinician.
- Time to feel it
- Nobody has measured an onset for it in everyday use. In the studies it appears in, effects were read from blood calcium and hormone measurements over weeks, not from sensation.
- The first dose
- Day one is quiet. As a vitamin D receptor agonist it starts changing gene transcription within hours, which reads on blood calcium and parathyroid hormone rather than as a sensation.
- With regular use
- Weeks of use act on calcium and phosphate handling and on parathyroid hormone through the same receptor as active vitamin D. What that does outside research settings hasn't been measured.
- How well tolerated
- Vitamin D receptor agonists raise calcium absorption, so blood calcium needs watching. This is an investigational compound rather than a supplement, and any use belongs with a clinician.
- How it feels
- Subtle at best. Not a perceptible supplement.
- The overlooked benefit
- Its side chain was deliberately altered so the body clears it faster than the natural active form of vitamin D, and that one structural change is why its effect on calcium absorption differs.
1 to 4mg a day is where Inecalcitol works.
Source: Dusso et al. Am J Physiol Renal Physiol 2007; vitamin D analog research
The proof, claim by claim.
These words describe the research, not the molecule's worth. Research strength is how much work stands behind one claim, and it is never a product score.
Inecalcitol is documented in the library; the clinical read is in the queue. Nothing about the strength of the research prints until the read is done.
- vitamin D receptor activationIn vitro study
- gene transcription at vitamin D response elementsNarrative review
- blood calcium handling with a vitamin D analogueRandomised trial
Questions people ask about Inecalcitol.
- Should I take this?
- Only in clinical trials. Not a consumer product.
- Is it safe?
- Limited data. Generally considered well tolerated at normal doses, but consult your doctor.
- Where does it come from?
- Various sources. Check product labeling.
- Are there alternatives?
- For vitamin D, use regular vitamin D3 supplements.
- How long until it works?
- Varies. Most supplements need weeks to months.
- Can I get it from food?
- Possibly. Check dietary sources.
Why these belong in the same formula. Each row says what the basis is, from settled biochemistry through to a trial that measured the pair.
Any vitamin D receptor agonist raises transcription of the intestinal calcium transport proteins TRPV6 and calbindin, so more of a calcium dose is absorbed. Total calcium intake should be counted alongside an active vitamin D analogue rather than considered separately.
Cholecalciferol is hydroxylated to calcitriol, which binds the same vitamin D receptor that inecalcitol was designed to activate. Running both raises total receptor activation, so the combined load is what matters rather than either dose alone.
Calcifediol needs only the renal 1-alpha-hydroxylase step to become calcitriol, and calcitriol occupies the same receptor as the analogue. The two therefore add at the receptor and their calcium handling effects add with them.
Vitamin D receptor activation raises production of osteocalcin and matrix Gla protein, both of which are inert until vitamin K carboxylates their glutamate residues. Raising the protein without the carboxylating vitamin leaves the calcium-directing step incomplete.
The enzymes that hydroxylate vitamin D and the vitamin D binding protein both require magnesium to function normally. Magnesium status therefore sets part of the background against which a receptor agonist acts.
An activated vitamin D receptor cannot bind its DNA response elements alone; it pairs with the retinoid X receptor, whose own ligand comes from retinoid metabolism. Retinoid status therefore sits upstream of any vitamin D receptor signal. This is settled receptor biology and applies to any VDR agonist, analogue included. It is not evidence that supplementing retinoids changes what an analogue does.
The vitamin D receptor binds DNA through two zinc finger motifs that require zinc to hold their fold. Adequate zinc status is a structural precondition for the whole receptor family. This is textbook molecular biology rather than a supplement interaction with a measured size. No trial links zinc intake to the activity of this analogue.
Vitamin D receptor activation raises intestinal absorption of both calcium and phosphate and feeds into the FGF23 and parathyroid loop. An analogue with receptor activity sits in that same loop. Mineral panels move together rather than one at a time. This is established endocrine physiology, and monitoring is a clinician matter.
A 2025 report describes Faecalibacterium prausnitzii and host metabolism together yielding inecalcitol in the gut, with an associated mucosal IgA response in an animal model. That is a single mechanistic finding in animals, not a demonstrated human route. It does open the possibility that this compound is not purely exogenous. Read it as an early mechanistic lead.
Nothing specific on file for Inecalcitol. Match the label to the daily amount above, and tell your doctor what you take.
Not medical advice. Show the label to your pharmacist.What Inecalcitol actually does.
It is a lab-made lookalike of the active form of vitamin D and switches on the same receptor.
An activated vitamin D receptor heterodimerises with the retinoid X receptor and binds vitamin D response elements in target gene promoters, altering transcription.
Vitamin D receptor activation raises intestinal calcium and phosphate absorption and suppresses parathyroid hormone transcription, so any receptor agonist sits inside that regulatory loop.
Structural changes to the side chain of a vitamin D analogue alter how quickly it is cleared by CYP24A1 and how strongly it drives intestinal calcium absorption, which is why analogues differ from calcitriol in calcium handling.
Where Inecalcitol comes from.
It is made in a lab as a modified copy of active vitamin D. One 2025 animal study also found gut bacteria and the body can produce it together.
Chemically synthesised. The molecule is identical to the one a plant or an animal makes, and building it deliberately means a known purity, a fixed dose and no crop contaminants. For several nutrients this is the only route that reaches a usable amount.
Analogues of this class are built from secosteroid intermediates rather than isolated from a natural source. Inecalcitol does not occur in food at usable amounts.
The molecule is a modified 1,25-dihydroxyvitamin D3 skeleton carrying side-chain and A-ring changes. Route detail is held by the developer and is not publicly specified.
Secosteroid analogues are purified chromatographically and characterised by NMR and mass spectrometry, since stereochemistry at several centres determines receptor behaviour.
Inecalcitol has been handled as an investigational compound in clinical development rather than as a marketed supplement ingredient, so no consumer dosage form is established.
The commercial synthetic route and any consumer dosage form are not publicly disclosed.
Getting Inecalcitol from food.
The whole-food sources on file. A supplement closes the gap, it does not replace dinner.
A gram-for-gram figure (how much of each you would eat to match a dose) will appear here once it is sourced and reviewed. This page will not print a number it cannot cite.
The essence, in one line each.
- Inecalcitol derived from host and microbial metabolism was associated with a stronger intestinal IgA response in a mouse model of gut inflammation.Animal study. Qin et al., 2025 (BMC Medicine). PMID 40660288 ↗
- Combinations of tyrosine kinase inhibitors with inecalcitol showed greater activity than either agent alone in cultured human cells.In vitro study. Al-Ali et al., 2024 (Saudi Pharmaceutical Journal). PMID 38298828 ↗
These are the studies our verdict leans on, chosen from the 2 we read for Inecalcitol. The full linked list is below.
The studies, linked.
2 sources behind our Inecalcitol verdict: peer-reviewed studies and registered clinical trials. Every one links straight to PubMed, the journal, or ClinicalTrials.gov. Read them yourself.
- Clinical trialEfficacy Study of Inecalcitol in Combination With Decitabine in Acute Myeloid Leukemia Patients Unfit for Standard ChemotherapyClinicalTrials.gov ↗PHASE2 · 110 participants · Unknown
- Clinical trialPhase 2 Study to Assess Efficacy and Safety of Inecalcitol in Imatinib-Treated Residual Chronic Myeloid Leukaemia: INIM StudyClinicalTrials.gov ↗PHASE2 · 54 participants · Unknown
Evidence surfaced via Semantic Scholar (Allen Institute for AI) and ClinicalTrials.gov. Ranked by study type and citation weight, not cherry-picked.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.